WhelWomen's Health Evidence Lab
WHEL-C-179 · Exploratory evidence · 2/10

testosterone for endometriosis

A single patient anecdote claims testosterone 'cured' their endometriosis, with no supporting detail.

Origin · ApprovedPathway · Hypothesis-generation · pre-validationEvidence arm · Community reportsEvidence silent
How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Androgens may suppress estrogen-dependent endometrial tissue growth, potentially reducing endometriosis activity.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 2 of 10 overall, a exploratory reading, from a community rated exploratory in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Community arm · anchors the headline2.0 / 10 · Exploratory

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

Independence (patient accounts): 0 distinct account(s) across 1 thread(s) (author handles unavailable — counting distinct posts).

0 / 2

Rigor

The single claim is vague: 'testosterone cured my endo' gives no dose, timing, formulation, duration, or symptom specifics. There is nothing to assess specificity of the report.

0 / 2

Specificity

The drug (testosterone) and outcome (endometriosis resolution) are both named and linked, satisfying basic specificity. However, the link is asserted vaguely with no detail on how 'cured' was determined.

1 / 2

Plausibility

Endometriosis is hormonally driven, and androgens/anti-estrogenic hormonal therapies can suppress endometrial tissue, so a beneficial effect of testosterone is biologically conceivable. The strong 'cured' claim, however, exceeds what the mechanism would typically support.

1 / 2

Consistency

With only one report, there is nothing to compare against; no other accounts confirm or deny, and no dose/timing details are given to assess internal coherence.

0 / 2
How the scoring rubric works, in general

Independent reading, reported beside the score

One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.

MATRIX cross-reference

Every Cure’smachine-learned treatment-probability model, drawn from a biomedical knowledge graph across roughly 1,800 drugs and 22,000 diseases. It provides a model-based estimate of how plausible a drug-disease link is given the structure of biomedical knowledge, reported alongside the substrate’s own evidence.

For this pair. MATRIX maps this drug and disease in its graph but returned no treat-score for the pair, which can mean the predicted link fell below the model's publication threshold.

Scored over MATRIX’s own entities, confirming the same drug and disease: CHEBI:17347 (drug) and MONDO:0005133 (disease). Validate against the source: Every Cure’s MATRIX dataset ↗.

More on the MATRIX cross-reference and its provenance

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources
Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Community reports. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from